Jury Bats Down Synthon's Claim Against Pfizer
In another victory for brand name drug companies, a federal jury has rejected Dutch generics maker Synthon IP Inc.'s claim that Pfizer Inc.'s blockbuster blood pressure drug Norvasc violates its intellectual...To view the full article, register now.
Already a subscriber? Click here to view full article